Table 2 The medians and Weibull parameter of chemotherapy-induced peripheral neuropathy.
ATC classification (ATC code) | Total (ROR) | Case for ROR calculation (n) | Case for time-to-onset analysis (n) | Median (interquartile range) | Scale parameter, α (95% CI) | Shape parameter, β (95% CI) |
|---|---|---|---|---|---|---|
Antineoplastic and immunomodulating agents (L) | 238,138 | 2222 | 791 | 23.0 (7.0–67.0) | 49.09 (44.74–53.80) | 0.83 (0.79–0.88) |
Purine analogues (L01BB) | 1667 | 20 | 11 | 41.0 (16.0–80.0) | 82.73 (38.45–169.76) | 0.97 (0.57–1.47) |
Pyrimidine analogues (L01BC) | 28,960 | 212 | 23 | 22.0 (7.0–71.0) | 58.29 (32.19–102.05) | 0.82 (0.58–1.11) |
Vinca alkaloids and analogues (L01CA) | 4387 | 70 | 17 | 11.0 (5.0–46.5) | 33.95 (15.61–70.42) | 0.73 (0.49–1.02) |
Taxanes (L01CD) | 18,506 | 333 | 86 | 22.5 (6.0–82.5) | 46.88 (34.58–62.87) | 0.76 (0.64–0.89) |
sorbent-based paclitaxel (L01CD01) | 6529 | 231 | 67 | 35.0 (7.0–94.0) | 56.24 (40.06–77.91) | 0.78 (0.64–0.94) |
nanoparticle albumin-bound paclitaxel (L01CD01) | 1673 | 27 | 12 | 5.5 (3.0–29.3) | 13.01 (4.93–32.05) | 0.74 (0.44–1.13) |
Platinum compounds (L01XA) | 24,749 | 611 | 286 | 22.0 (6.0–68.5) | 50.22 (43.48–57.83) | 0.92 (0.83–1.01) |
carboplatin (L01XA02) | 6212 | 87 | 20 | 32.0 (3.8–83.8) | 49.54 (26.34–89.70) | 0.87 (0.57–1.26) |
oxaliplatin (L01XA03) | 8737 | 491 | 259 | 22.0 (7.0–68.0) | 51.48 (44.40–59.52) | 0.95 (0.85–1.05) |
Monoclonal antibodies (L01XC) | 44,931 | 374 | 132 | 32.5 (11.3–73.8) | 60.22 (48.38–74.53) | 0.87 (0.75–0.99) |
bevacizumab (L01XC07) | 11,048 | 121 | 48 | 15.0 (7.0–56.0) | 50.09 (32.25–76.35) | 0.78 (0.61–0.97) |
Protein kinase inhibitors (L01XE) | 21,336 | 50 | 24 | 37.5 (13.5–174.5) | 82.90 (46.74–142.25) | 0.81 (0.57–1.10) |
Other antineoplastic agents (L01XX) | 12,835 | 320 | 118 | 14.5 (7.8–41.3) | 33.19 (26.45–41.41) | 0.87 (0.76–0.99) |
bortezomib (L01XX32) | 2727 | 210 | 80 | 17.5 (8.5–40.0) | 31.80 (24.57–40.83) | 0.94 (0.79–1.10) |
Other immunosuppressants (L04AX) | 7454 | 86 | 48 | 15.5 (3.5–71.5) | 39.20 (25.15–59.86) | 0.73 (0.57–0.91) |
lenalidomide (L04AX04) | 5714 | 70 | 35 | 13.0 (2.0–43.0) | 26.80 (15.13–46.16) | 0.66 (0.50–0.84) |
